Customization of therapy for gastroesophageal adenocarcinoma patients
Gastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-03-01
|
| Series: | Chronic Diseases and Translational Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X1730110X |
| _version_ | 1828298859236818944 |
|---|---|
| author | Dilsa Mizrak Kaya Kazuto Harada Fatemeh G. Amlashi Maria Vasilakopoulou Jaffer A. Ajani |
| author_facet | Dilsa Mizrak Kaya Kazuto Harada Fatemeh G. Amlashi Maria Vasilakopoulou Jaffer A. Ajani |
| author_sort | Dilsa Mizrak Kaya |
| collection | DOAJ |
| description | Gastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can palliate symptoms, improve survival and provide a better quality of life. One of the most promising options for some patients with advanced stage GEAC is immunotherapy, which can result in durable responses. Numerous phase III trials evaluating targeted therapies in different lines are ongoing and it is hoped that better biomarkers will emerge to identify patients who can benefit from targeted agents and immunotherapy in the future. Surgery remains as the corner stone for localized GEAC and adjunctive therapies can increase the survival rates by about 10%. The high toxicity and low completion rates of adjuvant therapy led to the strategies of preoperative treatment. With the results of ongoing pre-operative therapy trials we will be able to determine the optimal adjunctive approach for resectable GEAC. Keywords: Therapy, Gastroesophageal adenocarcinoma, Esophageal adenocarcinoma, Gastric adenocarcinoma |
| first_indexed | 2024-04-13T12:47:14Z |
| format | Article |
| id | doaj.art-67582d5f1347400690565480df29ae11 |
| institution | Directory Open Access Journal |
| issn | 2095-882X |
| language | English |
| last_indexed | 2024-04-13T12:47:14Z |
| publishDate | 2018-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Chronic Diseases and Translational Medicine |
| spelling | doaj.art-67582d5f1347400690565480df29ae112022-12-22T02:46:20ZengWileyChronic Diseases and Translational Medicine2095-882X2018-03-0141817Customization of therapy for gastroesophageal adenocarcinoma patientsDilsa Mizrak Kaya0Kazuto Harada1Fatemeh G. Amlashi2Maria Vasilakopoulou3Jaffer A. Ajani4Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USADepartment of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USACorresponding author. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX 77030, USA. Fax: +1 93 745 1163.; Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USAGastroesophageal adenocarcinomas (GEACs) remain a global health problem. These are most often diagnosed at advanced stage and the estimated 5-year relative survival rate is about 5%. Although cure is not possible for patients with advanced GEAC, systemic therapy (chemotherapy or biochemotherapy) can palliate symptoms, improve survival and provide a better quality of life. One of the most promising options for some patients with advanced stage GEAC is immunotherapy, which can result in durable responses. Numerous phase III trials evaluating targeted therapies in different lines are ongoing and it is hoped that better biomarkers will emerge to identify patients who can benefit from targeted agents and immunotherapy in the future. Surgery remains as the corner stone for localized GEAC and adjunctive therapies can increase the survival rates by about 10%. The high toxicity and low completion rates of adjuvant therapy led to the strategies of preoperative treatment. With the results of ongoing pre-operative therapy trials we will be able to determine the optimal adjunctive approach for resectable GEAC. Keywords: Therapy, Gastroesophageal adenocarcinoma, Esophageal adenocarcinoma, Gastric adenocarcinomahttp://www.sciencedirect.com/science/article/pii/S2095882X1730110X |
| spellingShingle | Dilsa Mizrak Kaya Kazuto Harada Fatemeh G. Amlashi Maria Vasilakopoulou Jaffer A. Ajani Customization of therapy for gastroesophageal adenocarcinoma patients Chronic Diseases and Translational Medicine |
| title | Customization of therapy for gastroesophageal adenocarcinoma patients |
| title_full | Customization of therapy for gastroesophageal adenocarcinoma patients |
| title_fullStr | Customization of therapy for gastroesophageal adenocarcinoma patients |
| title_full_unstemmed | Customization of therapy for gastroesophageal adenocarcinoma patients |
| title_short | Customization of therapy for gastroesophageal adenocarcinoma patients |
| title_sort | customization of therapy for gastroesophageal adenocarcinoma patients |
| url | http://www.sciencedirect.com/science/article/pii/S2095882X1730110X |
| work_keys_str_mv | AT dilsamizrakkaya customizationoftherapyforgastroesophagealadenocarcinomapatients AT kazutoharada customizationoftherapyforgastroesophagealadenocarcinomapatients AT fatemehgamlashi customizationoftherapyforgastroesophagealadenocarcinomapatients AT mariavasilakopoulou customizationoftherapyforgastroesophagealadenocarcinomapatients AT jafferaajani customizationoftherapyforgastroesophagealadenocarcinomapatients |